Dr. Sohal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3199 Highland Ave
Cincinnati, OH 45219Phone+1 513-475-8500Fax+1 513-584-4281
Summary
- Dr. Davendra Sohal is an oncologist at the University of Cincinnati. His clinical focus is gastrointestinal malignancies, and his research focus is clinical trials, including Phase I trials, precision oncology trials, and multidisciplinary studies.
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2005 - 2008
- University of Alabama at BirminghamMPH, Epidemiology and Biostatistics, 2003 - 2005
- All India Institute of Medical SciencesClass of 2002, MD
Certifications & Licensure
- OH State Medical License 2012 - 2026
- PA State Medical License 2009 - 2012
- NY State Medical License 2008 - 2010
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
- Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
- Join now to see all
Publications & Presentations
PubMed
- 52 citationsA virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients.Michael J. Pishvaian, Edik M. Blais, R Joseph Bender, Shruti Rao, Simina M. Boca
JAMIA Open. 2019-10-07 - 102 citationsLactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.Tushar D. Bhagat, Dagny Von Ahrens, Meelad M. Dawlaty, Yiyu Zou, Joelle Baddour
Elife. 2019-11-01 - 149 citationsMetastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra Sohal, Erin B. Kennedy, Pelin Cinar, Thierry Conroy, Mehmet Sitki Copur
Journal of Clinical Oncology. 2020-08-05
Lectures
- A pilot clinical trial of p53/p16-independent epigenetic therapy for pancreatic ductal adenocarcinoma (PDA).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenoc...2019 ASCO Annual Meeting - 6/1/2019
- Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC).2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
- University of Cincinnati Researcher Receives Catalyst Research Award to Further Cancer ResearchDecember 7th, 2021
- Pre-Surgery Chemotherapy Is Possible for Early Stage Pancreatic Cancer PatientsJanuary 21st, 2021
- IP Paclitaxel Add-on Promising in Pancreatic CancerJuly 14th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: